List of Excipients in Branded Drug DIAZOXIDE

« Back to Dashboard

Generic Drugs Containing DIAZOXIDE

Company	Ingredient	NDC	Excipient
Par Health USA LLC	diazoxide	0254-1010	ALCOHOL
Par Health USA LLC	diazoxide	0254-1010	CARBOXYMETHYLCELLULOSE SODIUM
Par Health USA LLC	diazoxide	0254-1010	FD&C RED NO. 40
Par Health USA LLC	diazoxide	0254-1010	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in DIAZOXIDE?

# Of NDCs	Excipient
2	ALCOHOL
2	CARBOXYMETHYLCELLULOSE SODIUM
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6

Diazoxide Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Diazoxide is a legacy potassium-channel opener used mainly for congenital hyperinsulinism and hyperinsulinemic hypoglycemia. Its commercial formulation opportunity is concentrated in pediatric oral delivery, where suspension stability, dose uniformity, palatability, preservative selection, and dosing convenience create more value than new active-ingredient protection.

The reference product, Proglycem oral suspension, contains diazoxide at 50 mg/mL. Its excipient system uses sorbitol, propylene glycol, polysorbate 80, sodium saccharin, methylparaben, and water. The formulation is designed for an orally administered, ready-to-use suspension rather than a true aqueous solution.[1]

What excipients are used in diazoxide oral suspension?

The marketed diazoxide suspension uses a conventional excipient platform for a poorly water-soluble pediatric drug.

Formulation function	Reference excipient or strategy	Commercial relevance
Sweetening and bulk	Sorbitol	Improves palatability and provides liquid bulk; excessive exposure can cause gastrointestinal effects
Co-solvency	Propylene glycol	Supports wetting and dispersion; pediatric exposure requires regulatory assessment
Wetting and suspension support	Polysorbate 80	Helps disperse hydrophobic diazoxide particles
Sweetener	Sodium saccharin	Improves taste at low concentration
Preservation	Methylparaben	Supports multidose microbiological stability
Vehicle	Purified water	Primary liquid phase
Drug form	Micronized or finely dispersed diazoxide particles	Controls sedimentation, dose uniformity, and redispersibility

The principal formulation problem is not chemical synthesis. It is maintaining a uniform, palatable suspension across the product shelf life and throughout repeated pediatric dosing.

Why is diazoxide formulated as an oral suspension?

Diazoxide has limited aqueous solubility, making a suspension more practical than a conventional aqueous solution. A suspension also permits delivery of clinically relevant doses in a small volume without requiring large quantities of organic solvent or extreme pH adjustment.

The commercial formulation must control five performance attributes:

1. Sedimentation rate.
2. Ease and completeness of redispersion.
3. Dose uniformity between doses.
4. Chemical and microbiological stability.
5. Taste and mouthfeel.

For pediatric patients, the dose may be adjusted by body weight and administered several times daily. A formulation that settles rapidly or forms a compact sediment can produce underdosing early in the bottle and overdosing after vigorous redispersion. These risks are particularly important in congenital hyperinsulinism, where treatment is often chronic and administered by caregivers.

What is the best excipient strategy for a new diazoxide product?

The strongest near-term strategy is an improved pediatric suspension that preserves the 50 mg/mL concentration while reducing excipient burden and administration risk.

Suspension architecture

A development program should evaluate:

• Controlled particle-size distribution for diazoxide.
• High-shear wetting and deagglomeration.
• Low-to-moderate viscosity sufficient to slow sedimentation without making the product difficult to pour.
• Structured vehicles based on cellulose derivatives, xanthan gum, or other established suspending agents.
• Container orientation and shake-time requirements.
• Redispersion after long-term storage and temperature cycling.

The development target should be a suspension that redistributes after a short, label-defined shaking period. “Shake well” without a validated practical shaking method is a weak commercial position.

Surfactant selection

Polysorbate 80 is established in oral pharmaceuticals, but it can create supply, oxidation, and impurity-management considerations. A reformulated product could evaluate:

• Lower polysorbate 80 concentrations.
• Poloxamers.
• Lecithin-based systems.
• Nonionic surfactant combinations.
• Wetting through particle engineering rather than higher surfactant loading.

The commercial benefit is strongest if a new wetting system improves redispersion while lowering total excipient exposure.

Sweetener and taste-masking strategy

Sorbitol and sodium saccharin provide a workable taste platform, but diazoxide has an intrinsic bitter or medicinal taste that may remain perceptible after dilution.

Potential approaches include:

• Sucralose or acesulfame potassium as alternative sweeteners.
• Flavor systems compatible with diazoxide and the preservative system.
• Polymer-based taste masking.
• Ion-pairing or surface coating of particles.
• Smaller dose volume through higher drug loading, subject to dose-measurement controls.

Taste masking must be assessed after administration in the target pediatric population, not only through adult sensory panels. The relevant commercial endpoint is treatment persistence and caregiver acceptance.

Which diazoxide formulations have the greatest commercial potential?

Product concept	Technical opportunity	Regulatory route	Commercial assessment
Improved 50 mg/mL suspension	Better redispersion, taste, and dosing accuracy	ANDA if pharmaceutically equivalent; 505(b)(2) if formulation or clinical bridging differs materially	Highest near-term opportunity
Preservative-reduced suspension	Lower methylparaben or preservative-free multidose system	ANDA or 505(b)(2), depending on differences	Attractive for chronic pediatric use
Unit-dose suspension	Eliminates repeated bottle handling and dosing variability	Likely 505(b)(2) or new dosage-form pathway	Higher packaging cost but strong adherence value
Oral powder for reconstitution	Better shipping stability and flexible final volume	505(b)(2) or ANDA depending on equivalence	Useful for specialty distribution
Dispersible tablet or granule	Improved portability and reduced liquid handling	505(b)(2)	Potentially valuable for older children and adults
Compounding kit	Pharmacy preparation from validated components	Depending on structure, drug product or compounding pathway	Lower barrier but weaker branded differentiation
Higher-concentration suspension	Smaller dosing volume	Requires careful dose-error and safety evaluation	Commercially possible but clinically sensitive

A 50 mg/mL product is already concentrated. Increasing concentration may reduce administration volume but could increase dosing errors, settling risk, and accidental overdose consequences. The business case is therefore stronger for better usability at the existing concentration than for simple concentration escalation.

What pediatric excipient risks affect diazoxide development?

Sorbitol

Sorbitol can cause gastrointestinal discomfort, diarrhea, and osmotic effects at sufficient exposure. The risk is relevant in infants and children receiving repeated daily doses. A reformulator should calculate daily sorbitol exposure across the full weight-based dosing range rather than relying on per-dose concentration alone.

Propylene glycol

Propylene glycol is widely used but requires age- and dose-sensitive assessment in pediatric products. A lower-propylene-glycol or propylene-glycol-free system could provide a regulatory and marketing advantage if it maintains physical stability.

Methylparaben

Methylparaben is established in oral products, but preservative exposure is increasingly scrutinized in pediatric development. A preservative-free unit-dose product or a multidose system with validated microbiological protection could differentiate from the reference product.

Polysorbate 80

Polysorbate 80 can undergo oxidative and hydrolytic degradation, with product quality affected by peroxide and related impurity levels. Supplier qualification, compendial testing, and container-closure compatibility are important for long-term stability.

Sodium saccharin and flavors

Sodium saccharin is effective at low levels, but taste acceptance depends on the interaction among sweetener, flavor, diazoxide particle surface, and suspension viscosity. The best formulation may use a blended sweetener system rather than a single replacement.

What is the FDA regulatory status of diazoxide?

Diazoxide is an FDA-approved small-molecule drug. Proglycem oral suspension is approved for management of hypoglycemia due to hyperinsulinism associated with conditions including leucine sensitivity, islet-cell hyperplasia, nesidioblastosis, malignancy, and extrapancreatic malignancy.[1]

Regulatory item	Status
Active ingredient	Diazoxide
Drug class	Potassium-channel opener; antihypoglycemic agent
Primary indication	Hyperinsulinemic hypoglycemia
Reference dosage form	50 mg/mL oral suspension
FDA pathway for generic	ANDA, subject to pharmaceutical equivalence and bioequivalence requirements
Reformulated product pathway	ANDA or 505(b)(2), depending on formulation and labeling differences
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
New chemical entity exclusivity	Expired for this legacy active ingredient

A new diazoxide formulation would generally compete through formulation quality, pediatric usability, supply reliability, and commercial access rather than through new active-ingredient exclusivity.

What is the Orange Book status of diazoxide?

The key regulatory asset is the approved product and its therapeutic equivalence position, not a strong modern patent barrier. FDA Orange Book records should be reviewed for the current listing of NDA 018304, including any active patent information and reference-product designation.[2]

For a generic developer, the relevant filing analysis includes:

• Reference listed drug selection.
• Pharmaceutical equivalence to the 50 mg/mL suspension.
• Bioequivalence strategy for a locally acting liquid dosage form.
• Inactive-ingredient justification.
• Comparative dissolution or particle-size data where applicable.
• Labeling differences.
• Paragraph IV certification if any listed patent remains relevant.

A formulation applicant should not assume that an old product has no regulatory protection. Orange Book patent listings, FDA exclusivity records, and the current product label must be checked at the time of filing.

When does diazoxide lose exclusivity?

Diazoxide’s original statutory exclusivity periods expired decades ago. The commercial question is therefore whether any later-listed formulation, method-of-use, or regulatory exclusivity remains relevant to a proposed product.

No biosimilar exclusivity analysis applies because diazoxide is a small molecule. Generic entry is technically more likely than biosimilar competition, although the market may remain limited because congenital hyperinsulinism is a rare disease and the product has specialized manufacturing and distribution requirements.

How many patents cover diazoxide formulations?

The active ingredient itself is a legacy compound, and the core compound patent estate is not a meaningful current barrier to entry. Potentially relevant rights would instead involve:

• Specific suspension compositions.
• Particle-size or micronization controls.
• Taste-masking systems.
• Modified-release dosage forms.
• Unit-dose packaging.
• Manufacturing processes.
• New methods of treating defined hyperinsulinism populations.

A formulation patent has commercial value only if its claims cover a clinically meaningful product attribute and are difficult to design around. Broad claims to routine excipients such as sorbitol, polysorbate 80, or methylparaben are generally less defensible than claims tied to quantified composition ranges, particle-size limits, redispersion performance, stability, or a defined dosing advantage.

What patent litigation and Paragraph IV risks affect diazoxide?

Diazoxide does not have the high-profile patent litigation profile associated with newer oncology, immunology, or metabolic drugs. The principal generic risk is an ANDA challenge to the reference suspension, potentially combined with a Paragraph IV certification if an active Orange Book patent is listed.

Potential litigation positions would likely focus on:

• Whether the proposed suspension is pharmaceutically equivalent.
• Whether a formulation patent is properly listed.
• Whether the generic product infringes composition or process claims.
• Whether bioequivalence is adequately demonstrated.
• Whether a branded formulation patent covers a clinically meaningful difference.

A brand owner seeking to defend a reformulated diazoxide product would need claims with measurable technical limitations. A patent based only on substituting one common sweetener or thickener for another would face substantial design-around pressure.

Which companies are positioned to challenge or supply diazoxide?

The competitive field includes three groups:

Generic pharmaceutical companies

Companies with ANDA capabilities in oral liquids may pursue diazoxide if the reference product has sufficient demand and the manufacturing process is manageable. The limited patient population constrains market size, but chronic use can support specialty pricing.

Specialty and rare-disease companies

Rare-disease companies may have an incentive to develop differentiated products with improved dosing, formulation tolerability, or patient-support services. The commercial case improves if the product is paired with diagnosis, genetic testing, or specialized endocrine care.

Excipient and formulation suppliers

Excipient suppliers can capture value through:

• Pediatric suspension platforms.
• Low-peroxide surfactants.
• Preservative-free multidose packaging.
• Taste-masking technologies.
• Ready-to-use oral-liquid manufacturing.
• Analytical methods for particle size and dose uniformity.

For suppliers, the most defensible position is a validated formulation platform with manufacturing know-how rather than a single off-the-shelf excipient.

What manufacturing and intellectual-property barriers exist?

The manufacturing barrier is moderate, not high. Diazoxide suspension production requires controlled particle engineering, uniform wetting, validated mixing, filling accuracy, microbiological control, and reliable redispersion. These requirements are manageable for established oral-liquid manufacturers but can be difficult for smaller firms without suspension-processing capability.

Key process controls include:

• Drug-substance particle-size distribution.
• Milling or micronization conditions.
• Order of excipient addition.
• Hydration time for suspending agents.
• Mixing shear and temperature.
• Homogeneity during bulk hold.
• Fill-volume accuracy.
• Container-closure performance.
• In-use stability after opening.

Manufacturing know-how may provide practical protection even when patent protection is limited. A company that reliably produces a uniform, palatable suspension can maintain an advantage through regulatory history, supplier qualification, and customer trust.

How does diazoxide compare with competing hyperinsulinism treatments?

Treatment	Primary role	Formulation opportunity	Competitive effect on diazoxide
Diazoxide	Chronic medical treatment for hyperinsulinism	Pediatric suspension, alternative oral dosage forms	Core comparator
Octreotide	Alternative medical therapy in selected cases	Injectable or long-acting delivery	Can reduce diazoxide use where diazoxide is ineffective or poorly tolerated
Glucagon	Rescue or acute support	Injectable and emergency-use products	Not a direct chronic oral substitute
Surgical management	Selected congenital cases	No conventional excipient opportunity	Limits long-term drug use in some patients
Nutritional therapy	Adjunctive management	Specialized feeding products	May reduce required drug exposure but does not replace drug treatment in all patients

Diazoxide remains commercially relevant because it is an established oral treatment and avoids injection for many patients. Its disadvantages include fluid retention, hypertrichosis, gastrointestinal effects, and the practical burden of repeated liquid dosing.[1]

What licensing deals could support a diazoxide product?

The most practical transaction structures are:

1. A formulation license from a specialty developer to a generic manufacturer.
2. An excipient-platform license tied to pediatric suspension technology.
3. A contract-development and manufacturing agreement for a ready-to-use product.
4. A regional commercialization license for rare-disease distribution.
5. A co-development agreement combining formulation IP with an established diazoxide supply chain.

A license should define ownership of formulation data, process parameters, stability packages, regulatory correspondence, and improvements. For a mature active ingredient, the main value is likely to reside in formulation know-how, regulatory execution, and commercial distribution rather than in compound patents.

What generic launch scenarios exist for diazoxide?

Scenario 1: Direct generic suspension

A manufacturer launches an equivalent 50 mg/mL suspension. Price competition is the primary risk to the incumbent. Differentiation depends on supply reliability and pharmacy coverage.

Scenario 2: Improved pediatric suspension

A company introduces improved taste, reduced excipient burden, or better redispersion through a 505(b)(2) or differentiated generic strategy. This can support premium pricing if the benefit is documented.

Scenario 3: Unit-dose or reconstituted product

A new package format reduces dosing errors and improves specialty-pharmacy handling. Manufacturing and packaging costs are higher, but the product can target hospitals and caregivers seeking convenience.

Scenario 4: Compounded substitution

Compounding pharmacies provide alternatives during shortages or access restrictions. Compounded products can pressure branded pricing but typically lack the same stability, validation, and regulatory status as an approved product.

Key Takeaways

• Diazoxide’s primary commercial opportunity is formulation improvement, not new active-ingredient discovery.
• The reference product uses a 50 mg/mL oral suspension containing sorbitol, propylene glycol, polysorbate 80, sodium saccharin, methylparaben, and water.
• The strongest development targets are redispersion, taste masking, dose uniformity, lower excipient exposure, and pediatric dosing convenience.
• Preservative-free unit-dose packaging and propylene-glycol-reduced formulations offer credible differentiation.
• Diazoxide is a small molecule, so biosimilar risk is not relevant.
• Generic entry is more important than compound-patent risk.
• Formulation patents must claim measurable performance or composition limits to create meaningful commercial protection.
• Manufacturing know-how, specialty distribution, and regulatory execution may provide greater practical protection than the legacy patent estate.
• The best near-term product is an improved 50 mg/mL pediatric suspension with validated stability and caregiver-friendly dosing.

FAQs

Is diazoxide soluble enough for a liquid solution?

No. Diazoxide’s limited aqueous solubility supports use of a suspension rather than a simple aqueous solution. Particle engineering and wetting are central to product performance.

Can a diazoxide product be made without propylene glycol?

Potentially. A reformulation could use alternative wetting and suspension systems, but the substitute must preserve physical stability, dose uniformity, palatability, and microbiological quality.

Is a preservative-free diazoxide suspension commercially feasible?

Yes, but the packaging and microbiological-control strategy must change. Unit-dose containers or validated multidose systems are more credible than simply removing methylparaben from the existing bottle.

Would a higher-concentration diazoxide suspension improve adherence?

It could reduce dose volume, but it may increase dosing-error risk and suspension instability. The benefit must be demonstrated against the existing 50 mg/mL product.

Is diazoxide a candidate for a 505(b)(2) product?

Yes. A new dosage form, delivery system, or clinically differentiated formulation could potentially use the 505(b)(2) pathway, while a straightforward equivalent suspension would more naturally follow an ANDA route.

References

1. U.S. Food and Drug Administration. (2023). Proglycem (diazoxide) oral suspension, prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2016). Inactive Ingredient Database. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2022). General principles for evaluating the abuse deterrence of generic solid oral opioid drug products. U.S. Department of Health and Human Services.